Pyxis Oncology is trading 6.8% down today at $2.46 amid continued volatility following its late-June private placement financing.
- The company recently announced up to $114 million in gross proceeds through a common stock and warrant sale.
- Shares remain under pressure as investors digest the impact of dilution and the resulting warrant overhang.
- No fresh company-specific news has appeared since the financing deal was disclosed.